ArticleJournal of oral and maxillofacial pathology : JOMFP
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Areca nut, derived from the Aim: This study aims to examine how various processing methods and storage conditions of areca nut affect L929 fibroblastic cell lines. Materials and Methods: Five areca nut varieties which underwent different processing methods and five commercial areca nut products (without tobacco) from Karnataka, Kerala, and Gujarat were collected and extracted using a triple solvent solution. Cytoproliferative activity was assessed using the methyl thiazolyl tetrazolium (MTT) and Trypan blue dye exclusion assays. Varieties with the highest proliferative activity were further analysed by Reverse transcription-Polymerase chain reaction (RT-PCR) and immunofluorescence, targeting collagen, fibronectin, and α-SMA expression. Results: Certain areca nut extracts stimulated fibroblast proliferation. However, there were no significant differences across processing methods, storage conditions, or chemical treatments. Two areca nut varieties and one commercial product exhibited the highest expression of collagen, fibronectin, and α-SMA, confirmed by both RT-PCR and immunofluorescence. Conclusion: The elevated expression of fibrosis-related proteins in two areca nut varieties with differing processing and storage suggests a potential role in fibrosis development. Only one of five commercial products showed similar activity, indicating variability in commercial preparations. These findings underscore the importance of further research into how processing and storage influence areca nut's role in OSMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.